Table 3 Changes in signs and symptoms of psoriasis between baseline and week 24

 PASI (median, IQR)

6.9 (3.5, 18.6)

0.4 (0, 1.5)

0.002**

 BSA% (median, IQR)

10.9 (3.6, 20.3)

0.2 (0, 1.8)

0.003**

 DLQI (median, IQR)

10 (5, 15)

1.5 (0.75, 5.75)

0.003**

 VAS pain (median, IQR)

18.5 (11.75, 49.5)

7 (1, 14)

0.003**

 VAS global (median, IQR)

68 (45, 74)

8 (2.5, 26)

< 0.001**

 VAS physician (median, IQR)

35.5 (8.75, 62.75)

7 (1, 15)

0.011*

 TJC 78 (median, IQR) (mean ± SD)^†

0 (0, 3.75); 2.65 ± 5.11

0 (0, 2); 0.63 ± 1.17

0.102

 PsAID (median, IQR)

3.5 (1.65, 1.7)

1.35 (0.2, 2.35)

0.003**

 PASI (median, IQR)

6.9 (3.3, 15.4)

0.3 (0, 1.1)

0.007**

 BSA% (median, IQR)

9.2 (4.3, 18.1)

0.05 (0, 1)

0.013*

 DLQI (median, IQR)

12 (6.75, 15.75)

2 (0.75, 8.25)

0.013*

 VAS pain (median, IQR)

26 (14, 50)

4 (1, 23)

0.004**

 VAS global (median, IQR)

70 (61, 75)

12 (1, 38)

0.001**

 VAS physician (median, IQR)

37 (7, 50)

4 (1, 22)

0.036*

 TJC 78 (median, IQR) (mean ± SD)^†

1 (0, 4); 3.53 ± 5.67

0 (0, 2); 0.53 ± 0.92

0.038*

 PsAID (median, IQR)

3.7 (2.84, 6.01)

1.45 (0.25, 3.2)

0.005**